Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy: Correlation With Trigger PSA, PSA Velocity, PSA Doubling Time, and Metastatic Distribution
暂无分享,去创建一个
M. Picchio | A. Massaro | M. Marzola | D. Rubello | L. Rampin | P. Colletti | P. Castellucci | A. Ferretti | S. Chondrogiannis | G. Grassetto | A. Marcolongo | A. Al-Nahhas
[1] A. Massaro,et al. Phantom study of the impact of reconstruction parameters on the detection of mini- and micro-volume lesions with a low-dose PET/CT acquisition protocol. , 2012, European journal of radiology.
[2] F. Montorsi,et al. Prostate-Specific Antigen Velocity Versus Prostate-Specific Antigen Doubling Time for Prediction of 11C Choline PET/CT in Prostate Cancer Patients With Biochemical Failure After Radical Prostatectomy , 2012, Clinical nuclear medicine.
[3] P. Cumming,et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[4] C. Simeone,et al. Role of 11C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation , 2011, Japanese Journal of Radiology.
[5] H. Jadvar. Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.
[6] F. Montorsi,et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. , 2010, The Journal of urology.
[7] F. Montorsi,et al. PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[8] V. Bettinardi,et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[9] C. Nanni,et al. Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy , 2009, Journal of Nuclear Medicine.
[10] Andrew J Vickers,et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Catalona,et al. What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? , 2009, Nature Clinical Practice Urology.
[12] S. Tyldesley,et al. Pretreatment prostate‐specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen‐deprivation therapy , 2008, Cancer.
[13] A. Pupi,et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer , 2008, La radiologia medica.
[14] P. Carroll,et al. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. , 2008, The Journal of urology.
[15] Y. Jo,et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. , 2008, Urology.
[16] F. Mottaghy,et al. 11C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer , 2007, BJU International.
[17] L. Collette,et al. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. , 2007, European urology.
[18] A. Renshaw,et al. Prostate‐specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low‐risk prostate cancer , 2006, Cancer.
[19] V. Canzonieri,et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[20] Pankaj K Choudhary,et al. Critical analysis of prostate‐specific antigen doubling time calculation methodology , 2006, Cancer.
[21] M. Soloway,et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? , 2004, BJU international.
[22] S. Freedland,et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. , 2004, The Journal of urology.
[23] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[24] A. Partin,et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? , 2003, The Journal of urology.
[25] T. H. van der Kwast,et al. Guidelines for processing and reporting of prostatic needle biopsies , 2003, Journal of clinical pathology.
[26] M. Terris,et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. , 2003, Urology.
[27] F Fazio,et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.
[28] Steven Piantadosi,et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.
[29] T. Miki,et al. [Natural history of prostate cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.
[30] D. Grignon,et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. , 1999, Urology.
[31] T. Block,et al. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy , 1999, European Urology.
[32] W. Catalona,et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. , 1999, The Journal of urology.
[33] M. Banerjee,et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. , 1998, The Journal of urology.
[34] A W Partin,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[35] A. Belldegrun,et al. Positron emission tomography in urological oncology. , 1998, The Journal of urology.
[36] A. Aschoff,et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. , 1997, The British journal of radiology.
[37] P. Carroll,et al. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. , 1996, Urology.
[38] T. Stamey,et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.
[39] V. Ambrosini,et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[40] Y. Jo,et al. A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy , 2008, Prostate Cancer and Prostatic Diseases.
[41] M. Schwaiger,et al. The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[42] G. Glatting,et al. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[43] M. Terris,et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. , 2001, Urology.